Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632243 | 0.87 | CYP3A4 (0.39) | CYP17A1CYP3A4CYP21A2CYP19A1CYP11B1 | |
| SCHEMBL20031435 | 0.84 | AR (0.38) | FNTAFNTBPGGT1B | |
| SCHEMBL21632262 | 0.77 | CYP3A4 (0.38) | CYP17A1CYP3A4CYP21A2CYP19A1CYP11B1 | |
| SCHEMBL20031127 | 0.69 | FNTA (0.33) | FNTAFNTBPGGT1B | |
| SCHEMBL20031571 | 0.69 | SLC6A2 (0.33) | — | |
| SCHEMBL20031605 | 0.67 | FNTA (0.32) | FNTAFNTBPGGT1B | |
| SCHEMBL21631894 | 0.67 | CYP3A4 (0.44) | CYP17A1CYP3A4CYP21A2CYP19A1CYP11B1 | |
| SCHEMBL21632114 | 0.66 | NPBWR1 (0.31) | FNTAFNTBPGGT1B | |
| SCHEMBL20000651 | 0.65 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL20031125 | 0.65 | NPBWR1 (0.30) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200029563-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYLDIOXOLANE DERIVATIVES | PIP5K1B, PIP5K1A, PIP5K1C | CYP17A1 3174/4885CYP3A4 2019/4885CYP21A2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.